PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [
DTC
PET
TR1402
TSHR
thyroid
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
aheadofprint
Résumé
Thyroid cancer is the most common endocrine cancer, with differentiated thyroid cancers (DTCs) accounting for 95% of diagnoses. While most DTC patients are diagnosed and treated with radioiodine (RAI), up to 20% of DTC patients become RAI refractory (RAI-R). RAI-R patients have significantly reduced survival rates compared to patients who remain RAI-avid. This study explores [
Identifiants
pubmed: 38976794
doi: 10.1021/acs.molpharmaceut.4c00224
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM